Drug intelligence / Profile preview

QLS12010

Development stage: Phase 2
Lead developer: Shanghai Qilu Pharmaceutical Research Center
Modality: Small Molecules
Administration: Oral

Overview

QLS12010 is an orally administered, investigational small molecule drug developed by Shanghai Qilu Pharmaceutical Research Center (a subsidiary of Qilu Pharmaceutical Group). It is currently in early-phase clinical development (Phase 1) for immune-mediated inflammatory diseases including atopic dermatitis, hidradenitis suppurativa, and rheumatoid arthritis. The specific molecular target and mechanism of action for QLS12010 remain undisclosed, but the drug is hypothesized to modulate key immunological pathways relevant to these diseases. Its ongoing evaluation centers on safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy adults, with future trials planned in patient populations.[1][3][5][7][9][10]

Brand names: QLS12010QLS-12010QLS 12010
Other names: QLS12010QLS-12010QLS 12010

Beyond the preview

Go deeper on QLS12010.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on QLS12010.

Explore the full profile